Laura Richman, D.V.M., Ph.D., DACVP
Chief Development Officer
Laura was most recently senior vice president of R&D at Arcellx. Prior to that, she was the executive director of the University of Pennsylvania’s Gene Therapy Program, where she led the preclinical development of more than 20 gene therapy programs across central nervous system (CNS), liver, metabolic, ocular, and respiratory diseases. Before that, she was vice president, translational sciences, at MedImmune. Laura is an author of more than 60 publications and has led or co-led more than 50 Investigational New Drug (IND) applications and three Biologics License Applications (BLAs). She is a veterinary pathologist and molecular virologist by training, with a D.V.M. from the University of Wisconsin, Madison, and a Ph.D. from The Johns Hopkins School of Medicine.